BIOATLA INC has a total of 17 patent applications. Its first patent ever was published in 2019. It filed its patents most often in Australia, Canada and Singapore. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GENMAB HOLDING B V, SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO LTD and IMAGINAB INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 4 | |
#2 | Canada | 3 | |
#3 | Singapore | 3 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | Israel | 2 | |
#6 | Republic of Korea | 1 | |
#7 | United States | 1 | |
#8 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Computer technology | |
#5 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Microorganisms | |
#6 | Bioinformatics | |
#7 | Combinatorial chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Short Jay M | 14 |
#2 | Frey Gerhard | 10 |
#3 | Chang Hwai Wen | 9 |
#4 | Boyle William | 5 |
#5 | Short Jay | 1 |
#6 | Chang Hwai | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020252095A1 | Conditionally active anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereof | |
AU2019334864A1 | Conditionally active chimeric antigen receptors for modified T-cells | |
SG11202100961UA | CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY | |
CA3102391A1 | Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof |